SINGAPORE, July 30, 2024 /PRNewswire/ — Acclime, providing businesses with corporate, governance and advisory services globally, is proud to announce a new regional commercial leadership structure which sets the foundation for the next stage of growth for the company. This move underscores Acclime’s commitment to enhancing operational efficiency and regional expertise across its expansive network […]
Category Archives: Pr Newswire
Leading online lottery service provider enables Australians to enter international lottery draws online SYDNEY, July 30, 2024 /PRNewswire/ — TheLotter Australia is excited to announce a new addition: a user-friendly mobile app, available for both iOS and Android devices. This extension complements the already popular website, offering Australians a simple way to join the world’s […]
SEONGNAM, South Korea, July 30, 2024 /PRNewswire/ — Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment of idiopathic pulmonary fibrosis […]
SAN JOSE, Calif., July 30, 2024 /PRNewswire/ — DapuStor Corporation, a pioneer in high-performance data storage solutions, announced today that it is expanding its collaboration with Marvell to deliver breakthrough Flexible Data Placement (FDP) technology optimized for Quad-Level Cell (QLC) and Triple-Level Cell (TLC) Solid-State Drives (SSDs). This collaboration aims to revolutionize the storage industry […]
ONTARIO, Calif., July 30, 2024 /PRNewswire/ — Nature’s Miracle Holding Inc. (NASDAQ: NMHI) (“Nature’s Miracle” or the “Company”), today closed its previously announced underwritten public offering of 5,000,000 shares of common stock, par value $0.0001 per share, at a public offering price of $0.24 per share, for aggregate gross proceeds of $1.2 million prior to deducting underwriting […]
Pr Newswire
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
29
Jul
Jul
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly The expanded label for […]
Pr Newswire
iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
29
Jul
Jul
Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion NASHUA, N.H. and WILLIAMSVILLE, N.Y. and RALEIGH, N.C., July 29, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with Windsong Radiology Group, one of US Radiology Specialists, […]
29
Jul
Jul
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, and members of management will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held […]
Pr Newswire
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
29
Jul
Jul
Research Published in THE LANCET’s eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announces the peer-reviewed publication on the Phase II ChronEx study assessing the safety […]
Pr Newswire
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
29
Jul
Jul
– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., […]